PTCTHIGH SIGNALFINANCIAL10-K

PTCT achieved a dramatic turnaround with operating income swinging from -$302.6M to +$866.9M and operating cash flow improving by 760% to $711.2M positive.

This represents a fundamental transformation of the business from loss-making to highly profitable operations, indicating successful commercialization of their rare disease portfolio. The positive operating cash flow generation suggests the company has reached sustainable profitability and cash generation capabilities.

Comparing 2026-02-19 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

PTCT delivered exceptional financial performance with revenue growing 36% to $264.7M while achieving massive operational leverage, turning a $302.6M operating loss into an $866.9M operating profit. The company generated $711.2M in positive operating cash flow compared to negative $107.7M previously, while total assets expanded 70% to $2.9B and inventory surged 243% to support commercial growth. The dramatic improvement in stockholders' equity from negative $1.1B to negative $205.3M, combined with strong cash generation, signals a successful transition to sustainable profitability in the rare disease pharmaceutical space.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+760.4%
-$107.7M→$711.2M

Operating cash flow surged 760.4% — exceptional cash generation, highest quality earnings signal.

Operating Income
P&L
+386.5%
-$302.6M→$866.9M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+287.9%
-$363.3M→$682.6M

Net income grew 287.9% — bottom-line growth signals improving overall business health.

Inventory
Balance Sheet
+243.4%
$23.2M→$79.6M

Inventory surged 243.4% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Stockholders Equity
Balance Sheet
+81.3%
-$1.1B→-$205.3M

Equity base grew 81.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+70%
$1.7B→$2.9B

Asset base grew 70% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
+66.7%
$581.0M→$968.4M

Current liabilities surged 66.7% — significant near-term obligations; verify ability to meet short-term debt.

Current Assets
Balance Sheet
+66.5%
$1.4B→$2.3B

Current assets grew 66.5% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
+36.3%
$6.5M→$8.9M

Capital expenditure jumped 36.3% — major investment cycle underway; assess returns on deployment.

Revenue
P&L
+36.2%
$194.4M→$264.7M

Strong top-line growth of 36.2% — accelerating demand or successful expansion into new markets.

LANGUAGE CHANGES
NEW — 2026-02-19
PRIOR — 2025-02-27
ADDED
As of February 18, 2026, the registrant had 82,774,730 shares of Common Stock, $0.001 par value per share, outstanding.
Summary of Risk Factors We may be unable to continue to execute our commercial strategy for our products, fail to obtain renewal of, or satisfy the conditions of our marketing authorization for our products; Delays or failures in obtaining regulatory approval would materially impair our commercialization capabilities; We may be unable to continue to commercialize Translarna for nmDMD in the EEA if individual countries in the EU do not leverage Articles 117(3) and 5(1) of the EU Directive 2001/83 to allow continued commercial use of Translarna.
Business Overview We are a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders.
We are advancing a robust and diversified pipeline of transformative medicines as part of our mission to provide access to best-in-class treatments for patients with unmet medical needs.
Our strategy is to leverage our scientific expertise and global commercial infrastructure to optimize value for our patients and other stakeholders.
+7 more — sign up free →
REMOVED
As of February 25, 2025, the registrant had 78,869,368 shares of Common Stock, $0.001 par value per share, outstanding.
Summary of Risk Factors We may be unable to continue to execute our commercial strategy for our products, fail to obtain renewal of, or satisfy the conditions of our marketing authorization for our products; Delays or failures in obtaining regulatory approval would materially impair our commercialization capabilities; We may be unable to continue to commercialize Translarna for nmDMD in the EEA if the EC adopts the negative opinion issued by the CHMP for the renewal of the existing conditional authorization for Translarna.
Business Overview We are a global biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders.
Our ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines.
Our mission is to provide access to best-in-class treatments for patients who have little to no treatment options.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →